Checkpoint Therapeutics, Inc.

NASDAQ:CKPT

4.1 (USD) • At close April 25, 2025
Bedrijfsnaam Checkpoint Therapeutics, Inc.
Symbool CKPT
Munteenheid USD
Prijs 4.1
Beurswaarde 353,912,000
Dividendpercentage 0%
52-weken bereik 1.38 - 4.5
Industrie Biotechnology
Sector Healthcare
CEO Mr. James F. Oliviero III, C.F.A., CFA
Website https://www.checkpointtx.com

An error occurred while fetching data.

Over Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks

Vergelijkbare Aandelen

ChromaDex Corporation logo

ChromaDex Corporation

CDXC

7.87 USD

CVRx, Inc. logo

CVRx, Inc.

CVRX

6.73 USD

UroGen Pharma Ltd. logo

UroGen Pharma Ltd.

URGN

9.87 USD

Annexon, Inc. logo

Annexon, Inc.

ANNX

1.88 USD

Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

HOWL

0.891 USD

Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc.

JSPR

4.73 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)